Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Onconova Announces Positive Data of Oral Rigosertib in Advanced Head and Neck Cancer

Published: Wednesday, April 10, 2013
Last Updated: Wednesday, April 10, 2013
Bookmark and Share
Oral rigosertib progresses to phase 2 clinical trial in squamous cell head and neck cancers.

Onconova Therapeutics, Inc. announced that tolerability and favorable anti-tumor activity data from a Phase 1 trial evaluating oral rigosertib, a dual pathway inhibitor, in patients with advanced solid tumors including refractory metastatic head and neck cancer were presented at the American Association for Cancer Research (AACR) Annual Meeting. The presentation was made by Antonio Jimeno, MD, PhD, of the University of Colorado School of Medicine and Director of the University’s Head and Neck Cancer Medical Oncology Program.

The oral presentation by Dr. Jimeno entitled, “Phase 1 and molecular correlates study of oral rigosertib in patients with refractory metastatic head and neck cancer and advanced solid tumors,” reported on the safety and activity of rigosertib in 48 patients. The objectives of this study were to define dose limiting toxicity, to characterize the pharmacokinetic (PK) profile, and to identify anti-tumor activity. Oral rigosertib was generally well tolerated. Notably, two of the six metastatic head and neck squamous cell carcinoma patients, with disease refractory to previous platinum-based therapy, showed anti-tumor responses. These responses included a confirmed complete response (CR) as well as a confirmed partial response (PR). These patients have received single-agent oral rigosertib for 98 and 48 weeks, respectively.

“The encouraging data reported today at AACR, describing the tolerability and clinical activity of oral rigosertib in advanced head and neck cancer, have driven the initiation of an 80-patient, multi-institutional nationwide Phase 2 trial in this patient population. Additionally, two Phase 2 trials, supported by proof of activity in earlier Phase 1 trials, are currently exploring utility of oral rigosertib in transfusion-dependent lower-risk MDS patients,” commented François Wilhelm, MD, PhD, Chief Medical Officer of Onconova. “We believe that these findings provide clinical support for further investigation of oral rigosertib as a treatment for advanced solid tumors, including metastatic head and neck cancer.”

Rigosertib has been extensively studied in clinical trials conducted in the U.S., Europe, Japan and India, in patients with solid tumors and blood cancers, with more than 850 patients enrolled in Phase 1, 2 and 3 trials, including a pivotal randomized Phase 3 trial conducted under a special protocol assessment (SPA) for patients with higher-risk myelodysplastic syndromes (MDS) previously treated with hypomethylating agents. Rigosertib, a patented new chemical entity, has received orphan designation for MDS and pancreatic cancer.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

GVK Biosciences and Onconova Therapeutics Partner
Companies form novel joint development partnership to advance new drugs for cancer.
Thursday, January 10, 2013
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Study Questions Presence in Blood of Heart-Healthy Molecules from Fish Oil Supplements
A new study from the Perelman School of Medicine at the University of Pennsylvania questions the relevance of fish oil-derived SPMs and their purported anti-inflammatory effects in humans.
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Key Player in Diabetic Kidney Disease Revealed
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!